| 2005-03 |
SymBio Pharmaceuticals Limited established at Nishi-Shimbashi, Minato-ku, Tokyo |
| 2005-03 |
SymBio Pharmaceuticals Co., Ltd. established in Nishi-Shimbashi, Minato-ku, Tokyo. |
| 2005-07 |
Head office relocates to Shimbashi, Minato-ku, Tokyo |
| 2005-07 |
Head office moved to Shimbashi, Minato-ku, Tokyo. |
| 2005-12 |
License Agreement finalized with Astellas Pharma GmbH for SyB L-0501 (bendamustine) development & commercialization rights in Japan |
| 2005-12 |
Entered into a license agreement with Astel Pharma (Germany) for exclusive development and sale of the anticancer agent 'Bendamustine Hydrochloride' in Japan. |
| 2006-03 |
Manufacturer's License (packaging, labeling and storage) obtained from Tokyo Metropolitan Government |
| 2006-03 |
Obtained a permit from the Tokyo Metropolitan Government for pharmaceutical manufacturing (packaging, labeling, storage) (Permit No.: 13AZ200010). |
| 2007-03 |
License Agreement finalized with Astellas Deutschland GmbH for SyB L-0501 (bendamustine) development & commercialization rights in China (HK), Taiwan, Korea and Singapore |
| 2007-03 |
Entered into a license agreement with Astel Dichtlants (Germany) for exclusive development and sale of the anticancer agent 'SyB L-0501' in China, Korea, Taiwan, and Singapore. |
| 2008-08 |
License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Japan |
| 2008-08 |
Entered into a license agreement with Eisai Co., Ltd. regarding the anticancer agent 'SyB L-0501'. |
| 2009-03 |
SymBio Pharmaceuticals concludes Sublicense Agreement with Cephalon, Inc. for development and commercialization rights of bendamustine hydrochloride in China (HK) |
| 2009-03 |
Entered into a sublicense agreement with Cefalon Inc. (USA) granting development and commercialization rights for the anticancer agent 'SyB L-0501' in China. |
| 2009-05 |
License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Korea and Singapore |
| 2009-05 |
Entered into a license agreement with Eisai Co., Ltd. for the anticancer agent 'SyB L-0501' targeting Korea and Singapore. |
| 2010-10 |
Received Domestic Manufacturing and Marketing Approval for Anticancer Agent TREAKISYM |
| 2010-10 |
Obtained domestic manufacturing and sales approval for the anticancer agent 'TREAKISYM : ® :'. |
| 2010-12 |
Launched domestic sales of anticancer agent TREAKISYM |
| 2010-12 |
Commenced domestic sales of the anticancer agent 'TREAKISYM : ® :'. |
| 2011 |
Held a press conference for the establishment of Symbio Pharmaceutical Co., Ltd. |
| 2011-07 |
Onconova and SymBio Pharmaceuticals complete License Agreement for SyB L-1101/SyB C-1101 |
| 2011-07 |
Entered into a license agreement with Oncova Inc. (USA) regarding the anticancer agents 'SyB L-1101/SyB C-1101'. |
| 2011-10 |
Listed on Osaka Securities Exchange JASDAQ Growth Market |
| 2011-10 |
Listed on the Osaka Stock Exchange JASDAQ Growth market. |
| 2014-11 |
Head office relocates to Toranomon, Minato-ku, Tokyo |
| 2014-11 |
Head office moved to Toranomon, Minato-ku, Tokyo. |
| 2016-05 |
SymBio Pharma USA, Inc. established at Menlo Park, California, USA |
| 2016-05 |
SymBio Pharma USA, Inc. (SymBio Pharma USA Inc.) established in Menlo Park, California, USA. |
| 2016-05 |
Established SymBio Pharma USA, Inc. in Menlo Park, California, USA. |
| 2016-08 |
Approval for Domestic Manufacturing and Marketing of Anticancer Agent TREAKISYM for Additional Indication of Chronic Lymphocytic Leukemia |
| 2016-08 |
Obtained domestic manufacturing and sales approval for the additional efficacy of the anticancer agent 'TREAKISYM : ® :' against chronic lymphocytic leukemia. |
| 2016-12 |
SymBio Pharmaceuticals announces the NDA approval of TREAKISYM (bendamustine) for the additional indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma in Japan |
| 2016-12 |
Obtained domestic manufacturing and sales approval for the additional efficacy of the anticancer agent Treaxin® for untreated low-grade non-Hodgkin lymphoma and mantle cell lymphoma. |
| 2017-09 |
Eagle Pharmaceuticals (NASDAQ: EGRX) and SymBio Pharmaceuticals completed License Agreement for bendamustine liquid formulations (RTD Injection and RI Injection) development & commercialization rights in Japan *RTD: Ready-to-dilute, RI: Rapid Infusion |
| 2017-09 |
Entered an exclusive licensing agreement with Eagle Pharmaceuticals (USA) for the development and commercialization of Bendamustine liquid formulations (RTD and RI) in Japan. |
| 2018-07 |
TREAKISYM (bendamustine) has been newly included as a standard-of-care option in the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues 2018 |
| 2018-07 |
Treaxin® was newly included as a standard treatment option in the 2018 edition of the Hematologic Tumor Treatment Guidelines. |
| 2018-07 |
Treaxin® was newly included as a standard treatment option in the 2018 edition of the Hematologic Tumor Treatment Guidelines. |
| 2019-09 |
September 2019: Chimerix (USA) and anti-viral drug 'Brinshidohobiru' (excluding smallpox) entered into an exclusive global license agreement for development, sales, and manufacturing |
| 2019-09 |
Entered an exclusive global licensing agreement with Chimerix (USA) for the development, sale, and manufacture of the antiviral drug Brinshidobiv (excluding smallpox). |
| 2020-09 |
SymBio Pharmaceuticals receives approval of TREAKISYM Ready-To-Dilute (RTD) formulation |
| 2020-09 |
Obtained approval for the manufacturing and sales of Treaxin® liquid formulation (RTD). |
| 2020-12 |
Commencement of in-house sales of the anti-cancer agent TREAKISYM : ® |
| 2020-12 |
Commenced in-house sales of the anticancer agent Treaxin®. |
| 2021-01 |
Market Launch of TREAKISYM : ® : Ready-To-Dilute (RTD) Formulation |
| 2021-01 |
Released Treaxin® liquid formulation (RTD). |
| 2021-03 |
SymBio Pharmaceuticals receives approval of TREAKISYM : ® : (bendamustine) in combination with rituximab, and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphoma |
| 2021-03 |
Obtained approval for the combination therapy of Treaxin® and rituximab for relapsed or refractory diffuse large B-cell lymphoma, and also approval for the combination therapy of Treaxin®, rituximab, and polatuzumab vedotin. |
| 2021-04 |
SymBio Pharmaceuticals receives approval of TREAKISYM : ® : Ready-To-Dilute (RTD) Formulation in combination with rituximab ,and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphoma |
| 2021-04 |
Obtained approval for the combination therapy of Treaxin® liquid formulation (RTD) and rituximab for relapsed or refractory diffuse large B-cell lymphoma, and also approval for the combination therapy of Treaxin® liquid formulation (RTD), rituximab, and polatuzumab vedotin. |
| 2022-02 |
SymBio Pharmaceuticals receives approval of 10-minute Rapid Infusion (RI) administration of the TREAKISYM : ® : Liquid Formulation |
| 2022-02 |
Obtained approval for the Treaxin® liquid formulation (RI administration, 10-minute infusion). |
| 2023-12 |
Head office relocates within Toranomon, Minato-ku, Tokyo |
| 2023-12 |
Relocated headquarters to Toranomon, Minato-ku, Tokyo. |
